Common Contracts

Contract

Study Agreement • October 25th, 2021

• Contract Type
  Study Agreement
• Filed
  October 25th, 2021

AMENDMENT #3 TO CLINICAL STUDY AGREEMENT DODATEK #3 KE SMLOUVĚ O KLINICKÉM HODNOCENÍ This Amendment (the "Amendment") to the Clinical Study Agreement, dated 21-Aug-2017 (the “Agreement”), for the clinical study (the “Study”) conducted in accordance with the protocol PR-30- 5017-C entitled “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum- Based Chemotherapy” and any amendments thereto (the “Protocol”), is made by and between: Tento Dodatek (dále jen „Dodatek“) ke Smlouvě o klinickém hodnocení s datem 21. 08. 2017 (dále jen „Smlouva“) ke klinické studii (dále jen „Studie“) prováděné v souladu s Protokolem PR-30-5017-C s názvem: „Multicentrická randomizovaná dvojitě zaslepená klinická studie fáze 3 kontrolovaná placebem hodnotící udržovací léčbu Niraparibem u pacientek s pokročilým karcinomem vaječníků s klinickou odpovědí na prvoliniovou che